Name
GS4-10 - Neratinib + fulvestrant + trastuzumab for hormone-receptor positive, HER2-mutant metastatic breast cancer, and neratinib + trastuzumab for metastatic triple-negative disease: latest updates from the SUMMIT trial
Date & Time
Tuesday, December 7, 2021
Speakers
Virtual Session Link